Clinical Trials

187 enrolled 14 charts

Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer

NCT03737994 2026-03-18

Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

10 enrolled 17 charts

Lung Neoplasms

NCT05987644 2026-03-09

DURABLE

Phase 1/2 Recruiting

56 enrolled

CNSThoracic

Brain Neoplasms, Lung Neoplasms

NCT04302025 2026-03-06

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

99 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04589845 2026-03-06

Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

920 enrolled 1 FDA

Other solid neoplasm

Solid Tumors

NCT04774718 2026-03-06

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors

Phase 1/2 Recruiting

42 enrolled

CNS

Central Nervous System Neoplasms

NCT05170204 2026-03-06

HORIZON 1

71 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06862869 2026-03-06

Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy

Recruiting

800 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03194893 2026-02-20

A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer

200 enrolled

EndocrineThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Multiple Endocrine Neoplasia Type 2a

NCT06765109 2026-02-17

ALKAZAR

Phase 3 Recruiting

450 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms

NCT03768063 2026-01-29

IMbrella B

1,000 enrolled

Neoplasms

NCT06624059 2026-01-21

HORIZON 2

11 enrolled

LymphoidOther hematologic neoplasm

Carcinoma, Non-Small-Cell Lung

NCT05722886 2025-11-24

DETERMINE

Phase 2/3 Recruiting

825 enrolled

Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Hematologic Neoplasms

NCT04116541 2025-11-21

MegaMOST

455 enrolled

Neoplasm Metastasis

NCT03596866 2025-09-12

ALTA-3

Phase 3 Completed

248 enrolled 20 charts

303 enrolled 31 charts 1 FDA

ALK+ Advanced NSCLC

NCT07001384 2025-08-14

A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)

Phase 1 Recruiting

30 enrolled

Lymphoid

Lymphoma, Large-Cell, Anaplastic

NCT02075840 2025-07-25

ALEX

Phase 3 Completed

Carcinoma, Non-Small-Cell Lung

NCT04341181 2025-07-25

ProTarget

300 enrolled

Neoplasms

NCT02314481 2025-05-23

DARWINII

50 enrolled

Carcinoma, Non-Small-Cell Lung, Genomic Instability

NCT05713006 2025-05-01

Alectinib Pharmacokinetic in Patients With NSCLC

Phase 1/2 Recruiting

45 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03445000 2025-04-08

ALERT-lung

Phase 2 Terminated

14 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung

NCT05834348 2025-03-30

DELINOR

5,279 enrolled 10 charts

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06354387 2025-02-12

Alectinib in Combination with Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided with Serum RNase1 and Tumor Expression of PD-L1

8 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

770 enrolled

Rare Tumor

NCT03944772 2025-01-30

ORCHARD

247 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04551521 2025-01-08

CRAFT: The NCT-PMO-1602 Phase II Trial

72 enrolled

Phase NA Not yet recruiting

Neoplasm Metastasis

NCT06709274 2024-11-29

MOTION-NSCLC

342 enrolled

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06692491 2024-11-18

SPRING

200 enrolled

Rare Tumour

NCT04322890 2024-10-22

PIKACHU

6,000 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05014464 2024-09-20

ATPase

90 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05015010 2024-08-09

ALNEO

33 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06532149 2024-08-09

EROS

Recruiting

80 enrolled

OtherThoracic

Carcinoma, Non-Small-Cell Lung, Eunuchism, Erectile Dysfunction, Sexual Dysfunction, Physiological

NCT02091141 2024-07-23

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

GastrointestinalGenitourinary

673 enrolled 22 charts

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Neoplasms

NCT03546894 2024-07-15

A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors

111 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05159245 2024-07-15

FINPROVE

Other hematologic neoplasm

250 enrolled

Hematologic Neoplasms

NCT06339554 2024-04-01

TOSS-ALK

98 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04817956 2024-02-29

IMPRESS-N

3,000 enrolled

Phase EARLY_PHASE1 Withdrawn

Neoplasm Metastasis

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT05081674 2023-10-11

BLISS

154 enrolled

BreastGastrointestinalThoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04591431 2023-10-03

ROME

Phase 2 Unknown

400 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT03158389 2023-09-28

N²M²

Phase 1/2 Completed

228 enrolled

CNS

Glioblastoma

NCT04647110 2023-04-06

Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.

549 enrolled 28 charts

ALK-positive NSCLC

NCT05725200 2023-02-21

EVIDENT

40 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT03271554 2022-11-18

Treatment Registry of Alectinib in Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Korea

355 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03131206 2021-09-27

A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer

Phase 1/2 Terminated

5 enrolled 8 charts

Head & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Thyroid Neoplasms

NCT04115410 2020-05-28

PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study

Unknown

4,724 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02013219 2020-04-21

A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)

Phase 1 Completed

52 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03155009 2020-02-10

ATALK

44 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02604342 2019-10-29

Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib

Phase 3 Completed

119 enrolled 33 charts

Carcinoma, Non-Small-Cell Lung

NCT01801111 2018-11-02

A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment

Phase 1/2 Completed

138 enrolled 40 charts